WHO rejects Canadian-made COVID-19 vaccine from Medicago, with ties to big tobacco

WHO rejects Canadian-made COVID-19 vaccine from Medicago, with ties to big tobacco

The World Health Organization has rejected Medicago’s made-in-Canada COVID-19 vaccine, restricting the federal government’s ability to donate those doses to countries in need.

The federal government signed an agreement with Medicago in 2020 to buy 20 million doses once the vaccine was approved by Health Canada, with the option to purchase 56 million more.

Health Canada authorized Medicago’s two-dose Covifenz vaccine in February for adults 18 to 64.

In clinical trials, it was more than 70 percent effective at preventing COVID-19 infections and 100 percent effective against severe illness, before the Omicron wave.

Medicago president Takashi Nagao says the WHO has not yet given the company its rationale, but he believes it is because tobacco company Philip Morris owns about one-fifth of Medicago.

Last week, a senior WHO official said the UN body has strict policies about engaging with tobacco companies and arms manufacturers and as such, the review process for Medicago was on hold and it was likely its vaccine would not be accepted for an emergency-use licence.

 

— Ottawa, March 25, 2022

A vial of a plant-derived COVID-19 vaccine candidate, developed by Medicago, is shown in Quebec City on Monday, July 13, 2020 as part of the company’s Phase 1 clinical trials in this handout photo. The World Health Organization has rejected Medicago’s made-in-Canada COVID-19 vaccine, restricting Ottawa’s ability to donate the shots to countries in need. THE CANADIAN PRESS/HO, Medicago *MANDATORY CREDIT*
Medicago